相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Nicola Gaynor et al.
SEMINARS IN CANCER BIOLOGY (2022)
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application
Yu-Huan Yang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
Constantin N. Baxevanis et al.
SEMINARS IN CANCER BIOLOGY (2021)
The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis
Suad A. K. Shamis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences
Ilona Rybinska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Macrophage Polarization States in the Tumor Microenvironment
Ava J. Boutilier et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
HER2-targeted therapies - a role beyond breast cancer
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer
Ellen C. de Heer et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
The Tumor Microenvironment as a Driving Force of Breast Cancer Stem Cell Plasticity
Flavia Fico et al.
CANCERS (2020)
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diversity, Mechanisms, and Significance of Macrophage Plasticity
Massimo Locati et al.
Annual Review of Pathology-Mechanisms of Disease (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
CD10+ GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness
Shicheng Su et al.
CELL (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Ian Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates
Fu Li et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling
Xuguang Yang et al.
CANCER RESEARCH (2016)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Carsten Denkert et al.
MODERN PATHOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer
Zheng Ao et al.
CANCER RESEARCH (2015)
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D. Bear et al.
LANCET ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer
S. Busch et al.
ONCOGENE (2015)
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Clinical significance of macrophage heterogeneity in human malignant tumors
Yoshihiro Komohara et al.
CANCER SCIENCE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
The cellular and molecular origin of tumor-associated macrophages
Ruth A. Franklin et al.
SCIENCE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression
Candace A. Gilbert et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts
Fernando Calvo et al.
NATURE CELL BIOLOGY (2013)
Luminal breast cancer: from biology to treatment
Michail Ignatiadis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer et al.
PLOS ONE (2013)
Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
Jian Yang et al.
STEM CELLS (2013)
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
Catharina Medrek et al.
BMC CANCER (2012)
Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer
Rin Yamaguchi et al.
HUMAN PATHOLOGY (2012)
Tumour-infiltrating macrophages and clinical outcome in breast cancer
S. M. A. Mahmoud et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Leukocyte composition of human breast cancer
Brian Ruffell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome
Masako Yamashita et al.
BREAST CANCER (2012)
Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients
Erick Roman-Perez et al.
BREAST CANCER RESEARCH (2012)
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome
Michael J. Campbell et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer
Sandra A. O'Toole et al.
CANCER RESEARCH (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
Meredith M. Regan et al.
LANCET ONCOLOGY (2011)
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Nathan R. West et al.
BREAST CANCER RESEARCH (2011)
Expression of Vascular Notch Ligand Delta-Like 4 and Inflammatory Markers in Breast Cancer
Adrian M. Jubb et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis
Melinda Protani et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors
Edna Cukierman et al.
SEMINARS IN CANCER BIOLOGY (2010)
The polarization of immune cells in the tumour environment by TGFβ
Richard A. Flavell et al.
NATURE REVIEWS IMMUNOLOGY (2010)
A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases
Susana M. Campos et al.
CLINICAL BREAST CANCER (2009)
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation
Alberto Mantovani et al.
HUMAN IMMUNOLOGY (2009)
Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
Robert Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The angiogenic switch in carcinogenesis
Vanessa Baeriswyl et al.
SEMINARS IN CANCER BIOLOGY (2009)
The fibromatosis signature defines a robust stromal response in breast carcinoma
Andrew H. Beck et al.
LABORATORY INVESTIGATION (2008)
Stromal gene expression predicts clinical outcome in breast cancer
Greg Finak et al.
NATURE MEDICINE (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Stromal myofibroblasts predict disease recurrence for colorectal cancer
Tadashi Tsujino et al.
CLINICAL CANCER RESEARCH (2007)
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
Davide Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
J Cuzick et al.
BRITISH JOURNAL OF CANCER (2006)
Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis
B Uzzan et al.
CANCER RESEARCH (2004)
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults
EE Calle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Myofibroblasts and mechano-regulation of connective tissue remodelling
JJ Tomasek et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189
JF Simpson et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
